Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- JACOBIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer: primary endpoint…
- Japanese AMLIndependent statistical analysis of Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- JAVELIN Bladder 100A detailed statistical analysis of the randomized phase 3 JAVELIN Bladder 100 trial of avelumab plus best supportive care versus best supportive care in patients with urothelial cancer, including trial design, time-to-event…
- JAVELIN Merkel 200Independent statistical analysis of JAVELIN Merkel 200, evaluating avelumab in participants with Merkel cell carcinoma. Includes trial design, registered endpoints, planned statistical interpretation, safety, limitations, and statistical methods.
- JAVELIN Ovarian 100Independent statistical analysis of JAVELIN Ovarian 100, the phase 3 trial of avelumab-based strategies in previously untreated epithelial ovarian cancer, including progression-free survival, overall survival, statistical methodology, safety, and interpretation.
- JMDBAn independent statistical analysis of the randomized phase 3 JMDB trial of pemetrexed and cisplatin versus gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
- JULIETIndependent statistical analysis of the JULIET phase 2 study of tisagenlecleucel in adults with diffuse large B-cell lymphoma, covering trial design, the registry-defined overall response endpoint, planned statistical analysis, safety, interpretation, and…
- KAMELEONIndependent statistical analysis of A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors: primary endpoint results, effect estimate with confidence…
- KARISMA2Independent statistical analysis of KARISMA2, a randomized phase 2 trial evaluating low-dose tamoxifen for mammographic density reduction, including its non-inferiority framework, Wald testing, multiplicity adjustment, results, safety, and statistical interpretation.
- KarMMa-3Independent statistical analysis of the randomized phase 3 KarMMa-3 trial of bb2121 versus standard regimens in relapsed and refractory multiple myeloma, including its progression-free survival endpoint, trial design, statistical methodology, and planned…
- KATE2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced…
- KETAMINEIndependent statistical analysis of Administration of Ketamine to Prevent the Post-operative Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00210210).
- KEYNOTE-010Independent statistical analysis of KEYNOTE-010, including its randomized phase 2/3 design, overall survival, progression-free survival, response, safety, statistical methods, and interpretation.
- KEYNOTE-012Independent statistical analysis of KEYNOTE-012, a phase 1 non-randomized study of pembrolizumab in participants with advanced solid tumors, including trial design, registered endpoints, safety results, planned statistical methods, and interpretation.
- KEYNOTE-040Independent statistical analysis of KEYNOTE-040, a randomized phase 3 trial of pembrolizumab versus standard treatment for recurrent or metastatic head and neck squamous cell cancer, including overall survival, progression-free survival, response, statistical…
- KEYNOTE-054Independent statistical analysis of KEYNOTE-054, a randomized phase 3 trial of pembrolizumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-057An independent statistical analysis of KEYNOTE-057, a randomized phase 2 study of pembrolizumab and pembrolizumab-based investigational combinations in high-risk non-muscle invasive bladder cancer, including trial design, endpoints, planned statistical methods, and interpretation.
- KEYNOTE-158Independent statistical analysis of KEYNOTE-158, a phase 2 non-randomized study of pembrolizumab in participants with advanced solid tumors, including the registry-defined objective response rate endpoint and its statistical interpretation.
- KEYNOTE-164A detailed statistical analysis of KEYNOTE-164, a phase 2 single-group study of pembrolizumab in previously treated locally advanced unresectable or metastatic colorectal cancer, including its objective response endpoint, exact binomial methodology, design,…
- KEYNOTE-189Independent statistical analysis of KEYNOTE-189 (NCT02578680), a randomized phase 3 trial evaluating pembrolizumab with pemetrexed-platinum chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
- KEYNOTE-240Independent statistical analysis of KEYNOTE-240, a randomized phase 3 trial of pembrolizumab plus best supportive care versus placebo plus best supportive care in previously systemically treated advanced hepatocellular carcinoma.
- KEYNOTE-394Independent statistical analysis of KEYNOTE-394, a randomized phase 3 trial of pembrolizumab or placebo with best supportive care in Asian participants with previously treated advanced hepatocellular carcinoma.
- KEYNOTE-522Independent statistical analysis of KEYNOTE-522, a randomized phase 3 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab versus placebo as adjuvant therapy in triple-negative breast cancer.
- KEYNOTE-564Independent statistical analysis of KEYNOTE-564, a randomized phase 3 trial of pembrolizumab versus placebo in the adjuvant treatment of renal cell carcinoma after nephrectomy, including disease-free survival, trial design, statistical methodology, and…
- KEYNOTE-671Independent statistical analysis of KEYNOTE-671, a randomized phase 3 trial of pembrolizumab with platinum-doublet chemotherapy as neoadjuvant/adjuvant therapy for resectable stage II, IIIA, and resectable IIIB non-small cell lung cancer.
- KEYNOTE-756Independent statistical analysis of KEYNOTE-756, a randomized phase 3 trial evaluating pembrolizumab versus placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy in early-stage ER+/HER2- breast cancer.
- KEYNOTE-782Independent statistical analysis of Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- KEYNOTE-A18Independent statistical analysis of KEYNOTE-A18 (NCT04221945), a randomized phase 3 trial of chemoradiotherapy with or without pembrolizumab in locally advanced cervical cancer, including primary time-to-event results, secondary endpoints, cLDA, stratified analysis, and…
- KHLADIndependent statistical analysis of Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00953576).
- KOMETIndependent statistical analysis of Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- KRYSTAL-10Independent statistical analysis of KRYSTAL-10, a randomized phase 3 study of MRTX849 with cetuximab versus chemotherapy in patients with advanced colorectal cancer with KRAS G12C mutation.
- KRYSTAL-12Independent statistical analysis of KRYSTAL-12, the phase 3 randomized trial of adagrasib versus docetaxel in patients with advanced non-small cell lung cancer with a KRAS G12C mutation.
- Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LACCIndependent statistical analysis of the LACC trial (NCT00614211), evaluating laparoscopic or robotic radical hysterectomy versus total abdominal radical hysterectomy for cervical cancer.
- LAL1610Independent statistical analysis of Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LAP07Independent statistical analysis of LAP07, a phase 3 randomized trial evaluating gemcitabine-based treatment strategies and radiation therapy or erlotinib in locally advanced pancreatic cancer.
- LAPACTIndependent statistical analysis of the phase 2 LAPACT trial of nab-paclitaxel plus gemcitabine in locally advanced pancreatic cancer, including trial design, time-to-treatment-failure methodology, planned analysis, safety, limitations, and statistical interpretation.
- Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen: Complete Statistical AnalysisIndependent statistical analysis of Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen: primary endpoint results, effect estimate with confidence interval,…
- Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ): Complete Statistical AnalysisIndependent statistical analysis of Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- LARCAn independent statistical analysis of the LARC study of radiological markers in locally advanced rectal cancer, focusing on Likert Score from diffusion-weighted MRI and planned time-to-event analyses of progression and overall survival.
- LASORIndependent statistical analysis of Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- LCCC1407Independent statistical analysis of Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02276560).
- LCSSIndependent statistical analysis of LCSS (NCT06154928), a randomized crossover trial evaluating warm water in laparoscopic cholecystectomy patients with abdominal distention.
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LEAP-001Independent statistical analysis of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LEAP-004Independent statistical analysis of LEAP-004, a phase 2 single-group trial of lenvatinib plus pembrolizumab in participants with advanced melanoma previously exposed to anti-PD-1/PD-L1 therapy, including its objective response endpoint, statistical methodology, and…
- Learning Impairments Among Survivors of Childhood Cancer: Complete Statistical AnalysisIndependent statistical analysis of Learning Impairments Among Survivors of Childhood Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00576472).
- LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…